Marc van der Waude, Marc van der Waude, Nov 01, 2009
The purpose of this contribution is to explore the status types that settlements and reverse payments could have under Article 81 EC. It seeks to identify the elements of the legal tests which could possibly be applied to assess the legality of such settlements and, in particular, those providing for a value transfer from the originator to the generic firm. This will be done as follows: Section 2 summarizes the main findings of the Final Report on settlement agreements; Section 3 makes an inventory of relatively old case law that dealt with comparable issues or those related to patent settlement agreements; and Section 4 makes an attempt to distill a legal test from the two previous sections for the assessment of patent settlement agreements between originator and generic firms under EC competition law.
Links to Full Content
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh